- Antibodies
- New
- Biological Process >
- Cellular Compartment >
- Disease >
- Molecular Function >
- Pathway Biocarta >
- Pathway KEGG >
- Pathway Panther >
- Tissue >
- Tag
- Peptides
- Biological Process >
- Cellular Compartment >
- Disease >
- Molecular Function >
- Pathway Biocarta >
- Pathway KEGG >
- Pathway Panther >
- Tissue >
- Amino Acids
- Tag
- Biological Process >
- Proteins
- RNAi
- FL cDNA Clones
- Cell/Tissues/Lysates
Phospho-APG8b (MAP1LC3B)-T93 Antibody Blocking PeptideSynthetic peptide
| Country | United States
Ordering Information
|
|||
|---|---|---|---|---|
| Catalog # | Size | Availability | Price | |
| BP3645a | 0.1 mg 400 ul | In Stock | $ 45.00 | DISCONTINED INQUIRE CLICK INQUIRE Add to cart |
- Specification
- Citiations : 0
- Reviews
- Protocols
- Backgrounds
Phospho-APG8b (MAP1LC3B)-T93 Antibody Blocking Peptide - Product info | |
| Primary Accession | Q9GZQ8 |
| Clone Names | 80317108 |
| Calculated MW | 14688 Da |
Phospho-APG8b (MAP1LC3B)-T93 Antibody Blocking Peptide - Additional info | |
| Gene ID 81631 | |
| Target/Specificity The synthetic peptide sequence used to generate the antibody AP3645a was selected from the MAP1LC3B-T93 region of human Phospho-APG8b (MAP1LC3B)-T93. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay. | |
| Format Synthetic peptide was lyophilized with 100% acetonitrile and is supplied as a powder. Reconstitute with 0.1 ml DI water for a final concentration of 1 mg/ml. | |
| Storage Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C. | |
| Precautions This product is for research use only. Not for use in diagnostic or therapeutic procedures. | |
Phospho-APG8b (MAP1LC3B)-T93 Antibody Blocking Peptide - Protein Information | |
| Name MAP1LC3B | |
| Synonyms MAP1ALC3 | |
| Function Involved in formation of autophagosomal vacuoles (autophagosomes) | |
| Cellular Location Cytoplasm, cytoskeleton. Endomembrane system; Lipid-anchor. Cytoplasmic vesicle, autophagosome membrane; Lipid-anchor. Note=LC3-II binds to the autophagic membranes | |
| Tissue Location Most abundant in heart, brain, skeletal muscle and testis. Little expression observed in liver | |
Phospho-APG8b (MAP1LC3B)-T93 Antibody Blocking Peptide - Related products
AP10648a: APG8a/b (MAP1LC3A/B)
AP12484a: APG8b(MAP1LC3B) Antibody (N-term T29)
AP1802a: LC3 Antibody (APG8B) (N-term)
AP1802b: LC3 Antibody (APG8B) (C-term)
AP1802d: LC3 Antibody (APG8B) (T6)
AP1802e: APG8b (MAP1LC3B)-T93/Y99 Antibody (Center)
AP1803a: LC3 Antibody (APG8A/B)
AP1806a: Cleaved LC3B Antibody
AP3530a: Phospho-LC3B-T12 Antibody
AP3713a: Phospho-APG8b (MAP1LC3B)-T6 Antibody
AP3739a: Phospho-APG8b (MAP1LC3B)-T93/Y99 Antibody
AP3744a: Phospho-APG8b (MAP1LC3B)-T29 Antibody
AP3748a: Cleaved-APG8b (MAP1LC3B) Antibody
RI13151: MAP1LC3B predesign siRNA
BP10648a: Cleaved-APG8a/b (MAP1LC3A/B) Blocking Peptide
BP1802a: LC3 Antibody (APG8b) (N-term) Blocking Peptide
BP1802b: LC3 Antibody (APG8b) (C-term) Blocking Peptide
BP1802d: APG8b (MAP1LC3B) Antibody (T6) Blocking Peptide
BP1802e: APG8b (MAP1LC3B) Antibody (T93/Y99) Blocking Peptide
BP1803a: LC3 Antibody (APG8a/b) Blocking Peptide
BP1806a: Cleaved-LC3 Antibody (APG8b) Blocking Peptide
BP3530a: Phospho-LC3 (APG8b) - T12 Antibody Blocking Peptide
BP3645a: Phospho-APG8b (MAP1LC3B)-T93 Antibody Blocking Peptide
BP3713a: Phospho-APG8b (MAP1LC3B)-T6 Antibody Blocking Peptide
Phospho-APG8b (MAP1LC3B)-T93 Antibody Blocking Peptide - Research Areas
Abgent welcomes feedback from its customers.
If you have used an Abgent product and would like to share how it has performed, please click on the
"Submit Review" button and provide the requested information. Our staff will examine and post your
review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abgent.com.
Thank you for your support.
Provided below are standard protocols that you may find useful for product applications.
BACKGROUND
MAP1A and MAP1B are microtubule-associated proteins which mediate the physical interactions between microtubules and components of the cytoskeleton. These proteins are involved in formation of autophagosomal vacuoles (autophagosomes). MAP1A and MAP1B each consist of a heavy chain subunit and multiple light chain subunits. MAP1LC3b is one of the light chain subunits and can associate with either MAP1A or MAP1B. The precursor molecule is cleaved by APG4B/ATG4B to form the cytosolic form, LC3-I. This is activated by APG7L/ATG7, transferred to ATG3 and conjugated to phospholipid to form the membrane-bound form, LC3-II.Macroautophagy is the major inducible pathway for the general turnover of cytoplasmic constituents in eukaryotic cells, it is also responsible for the degradation of active cytoplasmic enzymes and organelles during nutrient starvation. Macroautophagy involves the formation of double-membrane bound autophagosomes which enclose the cytoplasmic constituent targeted for degradation in a membrane bound structure, which then fuse with the lysosome (or vacuole) releasing a single-membrane bound autophagic bodies which are then degraded within the lysosome (or vacuole).
REFERENCES
Baehrecke EH. Nat Rev Mol Cell Biol. 6(6):505-10. (2005) Lum JJ, et al. Nat Rev Mol Cell Biol. 6(6):439-48. (2005) Greenberg JT. Dev Cell. 8(6):799-801. (2005) Levine B. Cell. 120(2):159-62. (2005) Shintani T and Klionsky DJ. Science. 306(5698):990-5. (2004)Tanida I., et al. Int. J. Biochem. Cell Biol. 36:2503-2518(2004)He H., et al. J. Biol. Chem. 278:29278-29287(2003) Tanida I., et al. J. Biol. Chem. 279:36268-36276(2004)